AORT vs ZYME

The company exhibits a weak fundamental health with a Piotroski F-Score of just 2/9, indicating significant operational and financial concerns. Despite strong revenue growth of 18.4% and impressive recent earnings surprises, the negative profit margin (-2.16%) and negative ROE (-2.46%) reflect persistent profitability issues. Valuation metrics are stretched, with a Forward P/E of 50.97 and Price/Book of 4.65, while insider selling worth $9.73M signals management's lack of confidence. Although balance sheet liquidity is strong (Current Ratio: 3.93), the absence of Altman Z-Score and weak earnings quality undermine long-term sustainability.

ZYME exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a failing financial trajectory. Despite a strong liquidity position (Current Ratio 5.88) and low debt, the company has suffered a catastrophic revenue collapse of -91.90% YoY. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $4.67M in shares. The valuation is speculative, trading at a high Price/Sales multiple of 19.23 despite negative margins and shrinking top-line growth.